×
About 399,014 results

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
https://www.healio.com/hematology-oncology/sarcoma/news/online/{28102d3c-c28b-4f98-950f-daa7db22f27d}/first-line-doxorubicin-plus-trabectedin-effective-safe-for-metastatic-leiomyosarcoma

May 30th, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab plus axitinib prolongs survival in advanced renal cell carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{6fd3e596-60e7-440e-9640-032254a386c8}/pembrolizumab-plus-axitinib-prolongs-survival-in-advanced-renal-cell-carcinoma

May 28th, 2020 - First-line pembrolizumab plus axitinib extended survival among patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 KEYNOTE-426 study presented during the ASCO20 Virtual Scientific Program.

Patients With HNSCC Experience Longer PFS After Combination Pembrolizumab and Chemotherapy, Subsequent Therapy
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200208/full/

May 29th, 2020 - Patients treated with pembrolizumab or pembrolizumab plus chemotherapy as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had longer progression-free survival (PFS) after the next line of therapy than patients first treated with the EXTREME regimen, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 6505).

Pralsetinib Shows Clinical Activity in Multiple RET Fusion–Positive Tumors
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200186/full/

May 28th, 2020 - The investigational RET inhibitor pralsetinib (BLU-667) has demonstrated durable activity, regardless of RET fusion genotype, in multiple advanced solid tumor types, according to data from the phase I/II ARROW trial (Abstract 109). Earlier analyses showed a treatment effect in the phase II cohorts with RET fusion–positive non–small cell lung cancer and RET mutation–positive medullary thyroid ca...

Personal Protective Equipment During the Pandemic - APhA
https://www.pharmacist.com/sites/default/files/audience/APhACOVID19PPE_0920_web.pdf
APhA

The COVID-19 pandemic is rapidly evolving and has placed a tremendous strain on the health care system. With pharmacy personnel being one of the most accessible health care professionals on the front line, it is important that they stay safe and be protected. Pharmacists must be well informed about safety and have enough access to personal protective equipment (PPE) to keep themselves, their st...

Hepatocellular Carcinoma - A Review
https://www.nejm.org/doi/10.1056/NEJMra1713263?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed
New England Journal of Medicine; Villanueva A

Apr 10th, 2019 - Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in the context of cirrhosis, hepatitis B or C virus infection, or nonalcoholic steatohepatitis. Underlying liver disease limits therapeutic efficacy.

Metastatic Pancreatic Cancer: ASCO Guideline Update
https://ascopubs.org/doi/full/10.1200/JCO.20.01364
Journal of Clinical Oncology; Davendra P.S, .

The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment.

Scientific Review of COVID-19 and MATH+
https://covid19criticalcare.com/math-hospital-treatment/scientific-review-of-covid-19-and-math-plus/
Front Line Critical Care Alliance (FLCCC)

In December 2019, COVID-19, an illness characterized by pneumonia associated with the new coronavirus SARS-CoV-2 (COVID-19) emerged in Wuhan, China. On March 13, 2020, the United States declared a national emergency in response to the pandemic. The greatest impact that COVID-19 had was on intensive care units (ICUs), given that approximately 20% of hospitalized cases developed acute respiratory...

Updates in the Management of CLL/SLL: Sequencing Therapy and the Role of Minimal Residual Disease Testing
https://jnccn.org/view/journals/jnccn/18/12.5/article-p1756.xml
Journal of the National Comprehensive Cancer Network;

Evolving standard first-line approaches to the treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are once again focusing on the integration of minimal residual disease (MRD) status as a response assessment tool. MRD status correlates with clinical outcomes, therefore making it a good early indicator of response and expected outcomes, noted William G. Wierda, MD, Ph...

Neuroblastoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq?cid=eb_govdel

Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States.[4,5] The prevalence is about 1 case per 7,000 live births; the incidence is about 10.54 cases per 1 million per year in children younger than 15 years.

Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq?cid=eb_govdel
National Cancer Institute

Primary brain tumors, including craniopharyngiomas, are a diverse group of diseases that together constitute the most common solid tumor of childhood. Brain tumors are classified according to histology, but tumor location and extent of spread are important factors that affect treatment and prognosis.

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer
http://ascopost.com/News/59644
ASCO Post

Jan 13th, 2019 - Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen nuclei. Findings from the study were published by Heindl et al in Nature Communications.

FDA grants priority review to Keytruda for first-line treatment of advanced head and neck cancer
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/%7Bf7be7f0c-f55a-4770-89bf-caf27f834e43%7D/fda-grants-priority-review-to-keytruda-for-first-line-treatment-of-advanced-head-and-neck-cancer

Feb 10th, 2019 - The FDA granted priority review to pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The designation applies to use of pembrolizumab (Keytruda, Merck) — an anti-PD-1 agent — as monotherapy or in combination with platinum and 5-FU chemotherapy.

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
https://www.gastrojournal.org/article/S0016-5085(19)30057-5/pdf
Singal,A.,et al

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric...
https://meetinglibrary.asco.org/record/169297/abstract
Shah,M.,et al

Jan 16th, 2019 - Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. A phase I/Ib study of mFOLFOX6 + ADX revealed encouraging antitumor activity in patients (pts) with gastric or gastroesophageal junction (GEJ) adenocarcinoma (median first-line, progression-free survival [PFS] of 9.9 months)....

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
https://www.pnas.org/content/early/2019/01/10/1811067116
Blando,J.,et al

Jan 10th, 2019 - The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration in primary and metastatic pancreatic tumors compared with melanoma, which differs in its tumor/stromal distribution. Our data indicate that human panc...

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30029-4/fulltext
The Lancet Oncology; Moore,K.,et al

Mar 31st, 2019 - Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5–9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

The incidence of leukemia, lymphoma, and multiple myeloma among atomic bomb survivors: 1950 – 2001
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875218/
Radiation Research;

Dec 28th, 2013 - Incident cases used in the analyses presented here were identified by the Leukemia and Tumor/Tissue Registries in Hiroshima and Nagasaki with follow-up through the end of 2001 – 55 years after the bombings and 14 years beyond that used in the previous comprehensive report. Analyses are presented for all leukemias other than chronic lymphocytic leukemia (CLL) or adult T-cell leukemia (ATL) as a ...